/4552.T

4552.T Stock - JCR Pharmaceuticals Co., Ltd.

Q: What is the analyst price target for 4552.T?

Analyst price target information is not currently available for 4552.T.

Q: What is 4552.T's market cap?

Market capitalization information is not currently available for 4552.T.

Healthcare|Drug Manufacturers - General|JPX

$719.00+1.55%

+$11.00 (+1.55%) • Jan 16

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $790.90

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 4552.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.06

52W High$824.00

52W Low$386.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$33.07B	$42.87B	$34.34B	$51.08B	$30.09B
Gross Profit	$21.55B	$31.25B	$25.46B	$40.62B	$22.27B
Gross Margin	65.2%	72.9%	74.1%	79.5%	74.0%
Operating Income	$-6,841,000,000	$7.53B	$4.97B	$19.93B	$8.27B
Net Income	$-4,758,000,000	$5.51B	$3.77B	$14.51B	$6.89B
Net Margin	-14.4%	12.8%	11.0%	28.4%	22.9%
EPS	$-38.43	$44.13	$30.34	$117.26	$55.80

Company Overview

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Visit Website

Earnings History & Surprises

4552.T

Beat Rate

37%

Last 19 quarters

Avg Surprise

+22.1%

EPS vs Estimate

Beats / Misses

7/12

Last 12 quarters

Latest EPS

$18.50

Q4 2025

EPS Surprise History

Q1 24

-106.6%

$-0.75vs$11.38

Q2 24

-83.3%

$2.78vs$16.69

Q3 24

-81.0%

$1.61vs$8.49

Q4 24

-146.8%

$-7.14vs$15.27

Q1 25

-90.5%

$0.90vs$9.49

Q2 25

-208.4%

$-33.80vs$31.17

Q3 25

-202.8%

$-4.48vs$4.36

Q4 25

-9.3%

$18.50vs$20.39

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Jan 28, 2026	—	—	—	—
Q4 2025	Oct 30, 2025	$20.39	$18.50	-9.3%	✗ MISS
Q3 2025	Jul 30, 2025	$4.36	$-4.48	-202.8%	✗ MISS
Q2 2025	May 13, 2025	$31.17	$-33.80	-208.4%	✗ MISS
Q1 2025	Jan 31, 2025	$9.49	$0.90	-90.5%	✗ MISS
Q4 2024	Oct 30, 2024	$15.27	$-7.14	-146.8%	✗ MISS
Q3 2024	Jul 30, 2024	$8.49	$1.61	-81.0%	✗ MISS
Q2 2024	May 10, 2024	$16.69	$2.78	-83.3%	✗ MISS
Q1 2024	Jan 26, 2024	$11.38	$-0.75	-106.6%	✗ MISS
Q4 2023	Oct 25, 2023	$12.95	$29.19	+125.4%	✓ BEAT
Q3 2023	Jul 26, 2023	$7.56	$12.90	+70.6%	✓ BEAT
Q2 2023	May 11, 2023	$6.80	$1.64	-75.9%	✗ MISS
Q1 2023	Jan 31, 2023	$0.58	$20.96	+3513.8%	✓ BEAT
Q4 2022	Oct 26, 2022	$0.10	$-3.29	-3390.0%	✗ MISS
Q3 2022	Jul 27, 2022	$-1.24	$11.06	+991.9%	✓ BEAT
Q2 2022	May 12, 2022	$36.76	$12.82	-65.1%	✗ MISS
Q1 2022	Jan 27, 2022	$23.95	$29.79	+24.4%	✓ BEAT
Q4 2021	Oct 28, 2021	$23.95	$62.27	+160.0%	✓ BEAT
Q3 2021	Jul 29, 2021	$27.23	$12.39	-54.5%	✗ MISS
Q2 2021	May 13, 2021	$19.90	$29.35	+47.5%	✓ BEAT

Frequently Asked Questions about 4552.T

What is 4552.T's current stock price?

JCR Pharmaceuticals Co., Ltd. (4552.T) is currently trading at $719.00 per share. The stock has moved +1.55% today.

What is the analyst price target for 4552.T?

No analyst price targets are currently available for this stock.

What sector is JCR Pharmaceuticals Co., Ltd. in?

JCR Pharmaceuticals Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the JPX exchange.

What is 4552.T's market cap?

JCR Pharmaceuticals Co., Ltd. has a market capitalization of $87.71 billion, making it a large-cap company.

Does 4552.T pay dividends?

No, JCR Pharmaceuticals Co., Ltd. does not currently pay a dividend to shareholders.